CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation from institutional healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. The company said proceeds will support its strategy to acquire and advance new assets, along with working capital and general corporate purposes, while A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer